Immunotherapy with fusions of glioma cells, glioma initiating cells, and dendritic cells for patients with malignant glioma
Phase 2
Recruiting
- Conditions
- Malignant glioma (Grade 3 or 4 glioma in the WHO criteria)
- Registration Number
- JPRN-UMIN000023806
- Lead Sponsor
- Jikei University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)A patient who has an allergy to biological medicines. 2)A patient who has a past or current history of autoimmune disease. 3)A patient who has positive of HBs antigen, HIV antibody, HCV antibody, or HTLV antibody. 4)A patient who has sever immune deficiency. 5)A patient who is administrated steroids for a long period, and is difficult to stop it. 6)A patient who has sever infectious disease. 7)A patient who has sever lung disease (Class 3 or more in the Hugh-Jones classification). 8)A patient who has sever heart disease (Class 3 or more in the NYHA). 9)A patient who has uncontrollable diabetes. 10)A pregnant or lactating patient. 11)A patient who is involved in other clinical trials.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year overall survival (OS) rate (a group of initially diagnosed grade 4 glioma) 3-year OS rate (a group of initially diagnosed grade 3 glioma) 1-year OS rate (a group of recurrent glioma)
- Secondary Outcome Measures
Name Time Method 1-year progression free survival (PFS) rate (a group of initially diagnosed grade 4 glioma) 2-year PFS rate (a group of initially diagnosed grade 3 glioma) 6-month PFS rate (a group of recurrent glioma)